Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies

Phase 2

Terminated

• Conditions: Sickle Cell Anemia; Hemoglobinopathy; Thalassemia

• Registration Number: NCT00040469
• Lead Sponsor: Baylor College of Medicine

Brief Summary

The major goal of this study is to determine the risks and benefits of bone marrow transplants in patients with severe thalassemia or sickle cell disease. Participation in this project will be for two years.

Detailed Description

To do the bone marrow transplant, we must first kill the cells in the bone marrow that make the abnormal red blood cells that are found in patients with severe thalassemia or sickle cell disease.

We will do this by using three drugs: busulfan, cyclophosphamide, and CAMPATH-1H. CAMPATH-IH is an investigational drug. CAMPATH-1H is used to prevent participants from rejecting or refusing to let the donor blood cells grow in the body. After the drug treatment, participants will be given bone marrow from a brother or sister who has healthy bone marrow that matches.

Study Timeline

• Study Start: 2000-08
• Study First Submitted: 2002-06-26
• Study First Submitted QC: 2002-06-27
• Study First Posted: 2002-06-28
• Primary Completion: 2003-11-21
• Study Completion: 2003-11-21
• Status Verified: 2020-01
• Last Update Submitted: 2020-01-15
• Last Update Posted: 2020-01-18

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Trial Locations

Locations (2)

Texas Children's Hospital; 🇺🇸 Houston, Texas, United States

The Methodist Hospital; 🇺🇸 Houston, Texas, United States